Skip to main content

Table 1 Expression of amino-terminal ezrin inhibits metastasis of breast carcinoma cells

From: The membrane cytoskeletal crosslinker ezrin is required for metastasis of breast carcinoma cells

Cell linea Transfected with Primary tumour takes (%) Day of 1 cm tumour diameterb Day of sacrifice Metastasis (%)c
SP1 None 100% (13/13) 24 ± 7 35 23% (3/13)
AC2M2 None 100% (11/11) 30 ± 5 41 90% (10/11)
pCB6 Vector 100% (8/8) 33 ± 4 39 88% (7/8)
WTC4 WT ezrin 100% (7/7) 28 ± 4 41 88% (6/7)
WTC6 WT ezrin 100% (15/15) 26 ± 2 39 87% (13/15)
NTC6 N-term ezrin 38% (3/8) 40 ± 10* 47 0% (0/8)
NTC7 N-term ezrin 100% (8/8) 28 ± 1 39 38% (3/8)
NTB8d N-term ezrin 100% (5/5) 29 ± 3 41 0% (0/5)
  1. aPoorly metastatic parental SP1 cells or highly metastatic variant AC2M2 cells alone, or transfected with empty pCB6 vector, or a vector encoding wild-type (WT) ezrin or amino-terminal (N-term) ezrin, were transplanted (7.5 × 103 cells) into the mammary fat pad of syngeneic mice (see text). bDay to 1 cm tumour diameter was calculated by linear regression analysis of data from individual mice. Values are expressed as mean ± standard deviation. Clone NTC6 showed a significant increase (*) in the day of 1 cm tumour diameter compared with WTC4 and WTC6 (P = 0.012). Mice with NTC6 tumours were therefore killed approximately 1 week later to allow tumour growth to a comparable size. cAC2M2 cells showed significantly more metastases than did the parental SP1 cells ( P = 0.003; Fisher's exact test). Pooled results from three N-term ezrin expressing clones showed a significant reduction in metastases compared with two WT ezrin expressing clones ( P < 0.0001). Individual P values for NTC6, NTC7 and NTB8 are as follows (respectively): <0.0001, 0.002 and 0.002. dNTB8 is an N-term ezrin-expressing clone derived from an independent transfection of AC2M2 cells, and was transplanted as described above.